High materiality7/10
Leerink upgrades Innate Pharma to Outperform after lacutamab deal
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Leerink Partners initiates/outperforms Innate Pharma with target $4; posted price $2.22.
- Target: $4
- Posted price: $2.22
- Analyst firm: Leerink Partners
Key facts
- 01
Target: $4
- 02
Posted price: $2.22
- 03
Analyst firm: Leerink Partners
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.